REUTERS: U.S. regulators on Friday approved Gilead Sciences Inc’s Sovaldi as a potentially easier cure for chronic infection with the liver-destroying hepatitis C virus…
Hepatitis C, which is often undiagnosed, affects about 3.2 million Americans, killing more than 15,000 each year, mostly from illnesses such as cirrhosis and liver cancer.
Most patients will be treated with the $1,000-a-day drug for 12 weeks, resulting in a total list price of $84,000, according to Gilead spokeswoman Cara Miller… (more)
